In human, in the Pulmonary Hypertension and Angiogenic Cell Therapy (PHACeT) trial, patients with stable severe PAH received EPC overexpressing eNOS in order to restore the vascular homeostasis and endothelial function. The gene discussed is NOS3; the disease is pulmonary arterial hypertension.